Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KERYX BIOPHARMACEUTICALS INCKERX · Entity 161794 | General Counsel and Secretary | February 15, 2018 | February 16, 2018 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Legal Officer | September 04, 2026 | September 04, 2026 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Chief Legal Officer | July 28, 2025 | July 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KERYX BIOPHARMACEUTICALS INC
Report date February 15, 2018 · Filed February 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,069 |
Reported balance
After 2018-02-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-15 · Sale · Disposed 5,652 · Balance 126,069 F1: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2: Includes 50,415 shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
F2: Includes 50,415 shares of restricted stock.
Kymera Therapeutics, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,254 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 1,209 · Balance 55,416 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-09-04 · Sale · Disposed 3,025 · Balance 52,391 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-09-04 · Sale · Disposed 2,137 · Balance 50,254 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Relay Therapeutics, Inc.
Report date July 28, 2025 · Filed July 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 389,748 |
Reported balance
After 2025-07-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-28 · Sale · Disposed 1,637 · Balance 389,748 F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2: Includes 187,004 shares underlying RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 371,472 |
Reported balance
After 2025-07-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-07-29 · Sale · Disposed 18,276 · Balance 371,472 F3: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F4: Includes 144,611 shares underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,506 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2: Includes 187,004 shares underlying RSUs.
F3: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F4: Includes 144,611 shares underlying RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2021 Filed Nov 17, 2021 00:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 6,500 | $35.42 | $230,230.00 |
DisclosureSEC source: 0001209191-21-064872 · doc4.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,284 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.03 to $35.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 13,887 shares underlying RSUs. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 00:07 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 6,500 | $4.12 | $26,780.00 |
DisclosureSEC source: 0001209191-21-064872 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F2 · balance_after: Includes 13,887 shares underlying RSUs. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 01:21 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 293 | $36.87 | $10,802.91 |
DisclosureSEC source: 0001209191-21-057858 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,284 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 13,887 shares underlying RSUs. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 00:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-055784 · doc4.xml · derivative · entry 3 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,286 Underlying: Common Stock · 6,500 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 00:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 6,500 | $35.02 | $227,630.00 |
DisclosureSEC source: 0001209191-21-055784 · doc4.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,577 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 00:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 6,500 | $4.12 | $26,780.00 |
DisclosureSEC source: 0001209191-21-055784 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:28 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 293 | $35.81 | $10,492.33 |
DisclosureSEC source: 0001209191-21-044065 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,577 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 991 shares of restricted stock units ("RSUs") on June 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 14,879 shares underlying RSUs. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-039328 · doc4.xml · derivative · entry 3 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,786 Underlying: Common Stock · 6,500 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 6,500 | $35.00 | $227,500.00 |
DisclosureSEC source: 0001209191-21-039328 · doc4.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,870 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 6,500 | $4.12 | $26,780.00 |
DisclosureSEC source: 0001209191-21-039328 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 01:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-028861 · doc4.xml · derivative · entry 3 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,286 Underlying: Common Stock · 6,500 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 01:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 6,500 | $35.00 | $227,500.00 |
DisclosureSEC source: 0001209191-21-028861 · doc4.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,870 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. Read SEC document |
| April 26, 2021 Filed Apr 29, 2021 01:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 6,500 | $4.12 | $26,780.00 |
DisclosureSEC source: 0001209191-21-028861 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020. Read SEC document |
| March 26, 2021 Filed Mar 26, 2021 23:59 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 31,740 | $0.00 Strike: $34.25 | $0.00 |
DisclosureSEC source: 0001209191-21-023331 · doc4.xml · derivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,740 Underlying: Common Stock · 31,740 shares Expires 2031-03-25 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| March 26, 2021 Filed Mar 26, 2021 23:59 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 15,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023331 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,870 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-006365 · doc4.xml · derivative · entry 3 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,786 Underlying: Common Stock · 5,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 5,000 | $55.05 | $275,250.00 |
DisclosureSEC source: 0001209191-21-006365 · doc4.xml · nonDerivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 28, 2021 Filed Jan 30, 2021 02:00 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 5,000 | $4.12 | $20,600.00 |
DisclosureSEC source: 0001209191-21-006365 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 67,588 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-20-063480 · doc4.xml · derivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,588 Underlying: Common Stock · 67,588 shares Expires 2030-03-01 F1 · shares: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · derivative.underlying_shares: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · balance_after: On March 2, 2020, the reporting person was granted an option to purchase 67,588 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 16,897 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 50,691 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:15 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | PurchaseCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0000899243-20-019840 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: On July 20, 2020, the Reporting Person purchased 10,000 shares of common stock, par value $0.001 per share, of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 16:04 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 5,652 | $4.81 | $27,186.12 |
DisclosureSEC source: 0001114220-18-000021 · wf-form4_151881503397408.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,069 F1 · price: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 50,415 shares of restricted stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 17:18 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,541 | $4.81 | $7,412.21 |
DisclosureSEC source: 0001114220-18-000013 · wf-form4_151743711456240.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,721 F1 · price: Sale of a total of 1,541 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on January 26, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 66,666 shares of restricted stock. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 18:06 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 753 | $4.69 | $3,531.57 |
DisclosureSEC source: 0001114220-18-000004 · wf-form4_151545276854523.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,262 F1 · price: Sale of a total of 753 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on January 4, 2018. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 71,145 shares of restricted stock. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:11 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,405 | $6.03 | $8,472.15 |
DisclosureSEC source: 0001114220-17-000039 · wf-form4_150948067069170.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,015 F1 · price: Sale of a total of 1,405 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 27, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 73,134 shares of restricted stock. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 17:25 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 630 | $7.19 | $4,529.70 |
DisclosureSEC source: 0001114220-17-000032 · wf-form4_150732510244312.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,420 F1 · price: Sale of a total of 630 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on October 4, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 77,613 shares of restricted stock. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 16:28 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,445 | $7.14 | $10,317.30 |
DisclosureSEC source: 0001114220-17-000024 · wf-form4_150161932168614.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,050 F1 · price: Sale of a total of 1,445 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on July 28, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 79,602 shares of restricted stock. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 17:59 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 641 | $7.67 | $4,916.47 |
DisclosureSEC source: 0000899243-17-018004 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,495 F1 · price: Sale of a total of 641 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on July 3, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 84,081 shares of restricted stock. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,441 | $5.97 | $8,602.77 |
DisclosureSEC source: 0000899243-17-011609 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,136 F1 · price: Sale of a total of 1,441 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 4,480 shares of restricted stock on April 28, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 86,070 shares of restricted stock. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,090 | $5.75 | $6,267.50 |
DisclosureSEC source: 0000899243-17-010411 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,577 F1 · price: Sale of a total of 1,090 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 3,333 shares of restricted stock on April 14, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 90,550 shares of restricted stock. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 642 | $5.80 | $3,723.60 |
DisclosureSEC source: 0000899243-17-009647 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,667 F1 · price: Sale of a total of 642 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,989 shares of restricted stock on April 4, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 93,883 shares of restricted stock. Read SEC document |
| February 14, 2017 Filed Mar 15, 2017 18:28 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantEmployee Stock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0000899243-17-007646 · doc4.xml · derivative · entry 2 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2027-02-14 F3 · derivative.exercise_date: The options vest according to the following schedule: one-third of the 97,500 options will vest on February 14, 2018 and one-twelfth will vest on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020. Read SEC document |
| February 14, 2017 Filed Mar 15, 2017 18:28 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 48,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007646 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,309 F1 · shares: The 48,750 shares are restricted common stock, with one-third of the 48,750 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020. F2 · balance_after: Includes 95,872 shares of restricted stock. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 6,984 | $4.65 | $32,475.60 |
DisclosureSEC source: 0000899243-17-002276 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,559 F1 · price: Sale of a total of 6,984 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 17,917 shares of restricted stock on January 27, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 47,122 shares of restricted stock. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,265 | $6.24 | $7,893.60 |
DisclosureSEC source: 0000899243-17-001438 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,543 F1 · price: Sale of a total of 1,265 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 3,333 shares of restricted stock on January 14, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 65,039 shares of restricted stock. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 16:06 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 759 | $6.16 | $4,675.44 |
DisclosureSEC source: 0000899243-17-000674 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,808 F1 · price: Sale of a total of 759 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,990 shares of restricted stock on January 4, 2017. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 68,372 shares of restricted stock. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,106 | $4.86 | $5,375.16 |
DisclosureSEC source: 0000899243-16-031825 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,567 F1 · price: Sale of a total of 1,106 shares of common stock was made in order to satisfy Mr. Adams income tax withholding obligation upon the vesting of 3,333 shares of restricted stock on October 14, 2016. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 70,362 shares of restricted stock. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 647 | $5.38 | $3,480.86 |
DisclosureSEC source: 0000899243-16-031390 · doc4.xml · nonDerivative · entry 1 Adams Brian · CIK 0001636994 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,673 F1 · price: Sale of a total of 647 shares of common stock was made in order to satisfy Mr. Adams' income tax withholding obligation upon the vesting of 1,990 shares of restricted stock on October 4, 2016. Mr. Adams had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 73,695 shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.